All In Biotech

Drug Trial Radar · NCT03466411

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,409 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,409

Actual

Start

Apr 13, 2018

Primary completion

Oct 20, 2023

Study completion Jan 28, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 15, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

Conditions

  • Crohn's Disease

Interventions

  • Guselkumab Dose 1Drug

    Guselkumab will be administered by IV infusion.

  • Guselkumab Dose 2Drug

    Guselkumab will be administered by SC injection.

  • Guselkumab Dose 3Drug

    Guselkumab will be administered by IV infusion.

  • Guselkumab Dose 4Drug

    Guselkumab will be administered by IV infusion.

  • Guselkumab Dose 5Drug

    Guselkumab will be by SC injection.

  • GuselkumabDrug

    Guselkumab will be administered by IV infusion and SC injection.

  • UstekinumabDrug

    Ustekinumab will be administered by IV infusion and SC injection.

  • PlaceboDrug

    Placebo will be administered as IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GALAXI 1: Change From Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 12Time frame: Baseline and Week 12
  2. Global: GALAXI 2: Percentage of Participants With Both Clinical Response at Week 12 and Clinical Remission at Week 48Time frame: Weeks 48
  3. Global: GALAXI 2: Percentage of Participants With Both Clinical Response (CR) at Week 12 and Endoscopic Response (ER) at Week 48Time frame: Weeks 48
  4. Global: GALAXI 3: Percentage of Participants With Both Clinical Response at Week 12 and Clinical Remission at Week 48Time frame: Weeks 48
  5. Global: GALAXI 3: Percentage of Participants With Both Clinical Response (CR) at Week 12 and Endoscopic Response (ER) at Week 48Time frame: Weeks 48
  6. Regional: GALAXI 2: Percentage of Participants With Clinical Remission at Week 12Time frame: Week 12
  7. Regional: GALAXI 2: Percentage of Participants With Endoscopic Response at Week 12Time frame: Week 12
  8. Regional: GALAXI 3: Percentage of Participants With Clinical Remission at Week 12Time frame: Week 12
  9. Regional: GALAXI 3: Percentage of Participants With Endoscopic Response at Week 12Time frame: Week 12

Locations

579 sites in 43 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialists of the Southeast

    Dothan, Alabama

  • Internal Medicine Center

    Mobile, Alabama

  • University of Arizona

    Tucson, Arizona

  • Advanced Research Center Inc

    Anaheim, California

  • Paul Wallace MD

    Beverly Hills, California

  • University Of California San Diego

    La Jolla, California

  • Om Research LLC

    Lancaster, California

  • Allameh Medical Corp

    Mission Viejo, California

  • United Gastroenterologists

    Murrieta, California

  • Clinnova Research

    Orange, California

  • Inland Empire Liver Foundation

    Rialto, California

  • UC Davis Medical Center

    Sacramento, California

  • Clinical Applications Laboratories, Inc

    San Diego, California

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado

  • Pioneer Research Solutions Inc.

    Coconut Creek, Florida

  • InvesClinic, LLC

    Fort Lauderdale, Florida

  • Harmony Medical Research Institute, Inc.

    Hialeah, Florida

  • Elite Research Network - Nature Coast Clinical Research, LLC

    Inverness, Florida

  • SIH Research

    Kissimmee, Florida

  • Auzmer Research

    Lakeland, Florida

  • Florida Research Center Inc.

    Lakewood Rch, Florida

  • Homestead Associates in Research Inc

    Miami, Florida

  • Community Research Foundation, Inc.

    Miami, Florida

  • Sanchez Clinical Research, Inc

    Miami, Florida

  • Visionary Investigators Network

    Miami, Florida

  • Gastroenterology Group Of Naples

    Naples, Florida

  • Florida Hospital

    Orlando, Florida

  • Omega Research Consultants

    Orlando, Florida

  • Care Access Research, Orlando

    Orlando, Florida

  • Synexus Clinical Research US Inc 1

    Pinellas Park, Florida

  • Central Florida Internists

    Saint Cloud, Florida

  • Synergy Clinical Research

    St. Petersburg, Florida

  • Theia Clincial Research, LLC

    St. Petersburg, Florida

  • Clinical Research of West Florida

    Tampa, Florida

  • GCP Clinical Research

    Tampa, Florida

  • Florida Hospital Tampa

    Tampa, Florida

  • Alliance Clinical Research

    Tampa, Florida

  • Cleveland Clinic Florida

    Weston, Florida

  • Atlanta Gastroenterology Associates

    Atlanta, Georgia

  • Morehouse School of Medicine

    Atlanta, Georgia

Showing 40 of 579 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.